This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-surprise: Archive
Dragonfly Energy Holdings Corp. (DFLI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DRAGONFLY EGY (DFLI) delivered earnings and revenue surprises of +55.04% and +11.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DFLINegative Net Change DAKTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of +88.89% and -18.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PSTVNegative Net Change COONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Compared to Estimates, Applied Materials (AMAT) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Applied Materials (AMAT) give insight into how the company performed in the quarter ended July 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AMATNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BOLTNegative Net Change ELMDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IGCPositive Net Change PINCPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Genasys (GNSS) Reports Q3 Loss, Beats Revenue Estimates
by Zacks Equity Research
Genasys (GNSS) delivered earnings and revenue surprises of -27.27% and +1.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
GNSSPositive Net Change PVHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +22.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
RNXTPositive Net Change HQYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Evolv Technologies Holdings, Inc. (EVLV) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Evolv Technologies (EVLV) delivered earnings and revenue surprises of -177.78% and +11.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
EVLVNegative Net Change SAICNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -20.93% and -25.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PROFPositive Net Change MODVPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -89.36% and -2.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PIIINegative Net Change PHRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Applied Materials (AMAT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Applied Materials (AMAT) delivered earnings and revenue surprises of +5.98% and +1.42%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
AMATNegative Net Change AMBANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CoDiagnostics (CODX) delivered earnings and revenue surprises of +8.00% and -45.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CODXPositive Net Change PACSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DARENegative Net Change AUNAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of +3.39% and +4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MGNXNegative Net Change AYRWFNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
TOMI Environmental Solutions, Inc. (TOMZ) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TOMI Environmental Solutions (TOMZ) delivered earnings and revenue surprises of -100.00% and -41.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TOMZNegative Net Change BBCPNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Compared to Estimates, Nice (NICE) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Nice (NICE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NICENegative Net Change
earnings earnings-estimates-revisions earnings-surprise
XCel Brands (XELB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
XCel Brands (XELB) delivered earnings and revenue surprises of +26.00% and -28.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
XELBNegative Net Change CURVPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
INPLAY OIL CP (IPOOF) Q2 Earnings Miss Estimates
by Zacks Equity Research
INPLAY OIL CP (IPOOF) delivered earnings and revenue surprises of -80.77% and +3.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IPOOFPositive Net Change CSIQPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Tapestry (TPR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Tapestry (TPR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TPRNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Advance Auto Parts (AAP) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Advance Auto Parts (AAP) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AAPNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Here's What Key Metrics Tell Us About Deere (DE) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Deere (DE) give a sense of how the business performed in the quarter ended July 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DENegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Amcor (AMCR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Amcor (AMCR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AMCRNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Douglas Dynamics, Inc. (PLOW) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Douglas Dynamics (PLOW) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PLOWNegative Net Change SMPNegative Net Change
earnings-surprise price-change style-scores valuation
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
VYNEPositive Net Change CASIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Hasbro, Inc. (HAS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Hasbro (HAS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HASPositive Net Change
earnings-surprise price-change style-scores valuation